(AGENPARL) – Tue 02 September 2025 5.30 PM CEST / 2-Sep-2025 / Hansa Biopharma AB (STO:HNSA)
Lund, Sweden, September 2, 2025. Hansa Biopharma AB (publ), “Hansa” (Nasdaq
Stockholm: HNSA), has today on September 2, 2025 held its Extraordinary General
Meeting. The Extraordinary General Meeting was held by physical presence of
shareholders and with the option for shareholders to exercise their voting
rights by advance voting (postal voting). The Extraordinary General Meeting of
Hansa passed the following resolutions.
The number of members of the Board of Directors, election of new members of the
Board of Directors and fees for members of the Board of Directors
The Extraordinary General Meeting resolved that the members of the Board of
Directors shall be eight with no deputy members.
The Extraordinary General Meeting resolved that the fees for the Board of
Directors, for the period until the end of the next Annual General Meeting,
shall remain unchanged from what was resolved at the Annual General Meeting
2025, however that Natalie Berner and Michael Bologna have declined to receive
Board remuneration.
The Extraordinary General Meeting resolved on new election of Elisabeth Björk,
Natalie Berner and Michael Bologna as members of the Board, all for the time
until the end of the next Annual General Meeting. The current members of the
Board Eva Nilsagård, Hilary Malone, Mats Blom, Peter Nicklin and Jonas Wikström
remain as members of the Board and Anders Gersel Pedersen and Florian Reinaud
resigned as members of the Board in connection with the Extraordinary General
Meeting.
More information about the resolutions is available in the notice and the
complete proposals which are available on the company’s website,
http://www.hansabiopharma.com.
The information was submitted for publication, through the agency of the contact
person set out below, at 17:30 CEST on  September 2, 2025.
— ENDS —
Contacts for more information:
Evan Ballantyne, Chief Financial Officer
Notes to editors
About Hansa Biopharma
Hansa Biopharma AB is a pioneering commercial-stage biopharmaceutical company on
a mission to develop and commercialize innovative, lifesaving and life-altering
treatments for patients with rare immunological conditions. The company has a
rich and expanding research and development program based on its proprietary IgG
-cleaving enzyme technology platform, to address serious unmet medical needs in
autoimmune diseases, gene therapy and transplantation. The company’s portfolio
includes imlifidase, a first-in-class immunoglobulin G (IgG) antibody-cleaving
enzyme therapy, which has been shown to enable kidney transplantation in highly
sensitized patients and HNSA-5487, a next-generation IgG cleaving molecule with
redosing potential. Hansa Biopharma is based in Lund, Sweden, and has operations
in Europe and the U.S. The company is listed on Nasdaq Stockholm under the
ticker HNSA. Find out more at www.hansabiopharma.com and follow us
on LinkedIn (https://www.linkedin.com/company/hansa-medical-ab/).
©2025 Hansa Biopharma AB. Hansa Biopharma, the beacon logo, IDEFIRIX, and
IDEFIRIX flower logo are trademarks of Hansa Biopharma AB, Lund, Sweden. All
rights reserved.
If you would rather not receive future communications from Hansa Biopharma AB, please go to https://optout.ne.cision.com/en/oFS9We4GkmX79JRaABsd1HR8QYK5XWsb8pMfPjFjtqNr9Ts2ZZbiKkygxnBuB9eXozV4SdMjnTTXm8HJ9bnVA3c7cRYTEQ4xHTBq6fVbba4c6.
Hansa Biopharma AB, Scheelevägen 22, Lund, 22362 Sweden
————————————————————
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
If you would rather not receive future communications from Hansa Biopharma AB, please go to https://optout.ne.cision.com/en/oFS9We4GkmX79JRaABsd1HR8QYK5XWsb8pMfPjFjtqNr9Ts2ZZbiKkygxnBuB9eXozV4SdMjnTTXm8HJ9bnVA3c7cRYTEQ4xHTBq6fVbba4c6.
Hansa Biopharma AB, Scheelevägen 22, Lund, 22362 Sweden
Report this content